Product
Nivolumab Placebo
1 clinical trial
1 indication
Indication
MelanomaClinical trial
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2016-08-01